STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses for the eye, today
announced its partnership with Will Levis, quarterback for the
Tennessee Titans of the National Football League (NFL). This
partnership will raise awareness of the EVO Implantable Collamer®
Lenses (EVO ICL). The EVO ICL is a vision correction device that
works in harmony with your natural eye, provides clear vision1,2
day or night1,3, and does not cause contact lens induced dry eye or
dry eye syndrome4,5. EVO ICL is proud to provide athletes like
Levis with sharp1,2 vision day or night1,3, on and off the
field.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230809191942/en/
Will Levis, Titans QB, upgraded his
vision with EVO ICL. (Photo: Business Wire)
The FDA-approved EVO ICL lenses are successful in correcting
myopia, which affects distance vision, and myopia with astigmatism,
which causes blurred vision at all distances. As a professional
athlete, Levis struggled with his eyesight for 12 years, making it
difficult to focus solely on the game while depending on his
contact lenses. Earlier this year, Levis had EVO lenses implanted
by his doctor to upgrade his vision and break free from the daily
hassles of contact lenses and eyeglasses. Starting in September
2023, Levis will be sharing his journey with EVO to help drive
education and awareness of EVO ICL among the millions of Americans
who suffer from myopia and are looking for a proven and effective
vision correction solution.
“Getting the EVO lenses has been one of the best decisions I’ve
made, and I couldn't be more thrilled with the amazing results,”
said Levis. “The ability to wake up with sharp, clear vision has
been a game-changer. After learning about this cutting-edge
technology, choosing EVO to upgrade my vision was an easy decision.
As an athlete, I now have the confidence of knowing that my vision
won’t be a worry for me and that my contact lenses won’t bother me
during a game. I can’t wait to take my EVO vision out on the field
this season.”
“As Will was looking at ways to prepare for his first NFL
season, he wanted a premium solution for vision correction. Once he
learned about EVO ICL and all of its benefits, EVO became an easy
choice for him,” said Tom Frinzi, CEO of STAAR Surgical.
The EVO procedure involves implanting (or adding) a proprietary,
biocompatible, flexible lens made from Collamer® into the eye
between the iris (colored part of the eye) and the natural lens to
correct/reduce nearsightedness and astigmatism. The entire EVO ICL
procedure typically takes about 20–30 minutes. Most patients
experience improved vision right after the procedure. The EVO lens
can permanently correct vision without removing corneal tissue and,
if desired, is removable by a doctor for added peace of mind. EVO
ICL gives the patient flexibility for the future, while also
helping to eliminate dependency on glasses and contact lenses
now.
Although the EVO ICL lens is new to the U.S. market, it has been
approved, marketed and successfully implanted by ophthalmologists
throughout Europe, Asia and the rest of the world. According to a
patient survey, 99.4% of patients would have the EVO ICL procedure
again.6 Over 2,000,000 ICLs have been delivered globally.
For more information about EVO Implantable Collamer® Lenses,
please visit https://evoicl.com.
References
- Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al.
Effect of the EVO+ Visian Phakic Implantable Collamer Lens on
Visual Performance and Quality of Vision and Life, Am J Ophthalmol
2021;226: 117–125.
- Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian
ICL: Six month results from the United States Food and Drug
Administration clinical trial. Clinical Ophthalmology.
2022;16:1541-53.
- Parkhurst GD. A prospective comparison of phakic collamer
lenses and wavefront-optimized laser-assisted in situ
keratomileusis for correction of myopia. Clin Ophthalmol. 2016 Jun
29;10:1209-1215.
- Ganesh S, Brar S, Pawar A. Matched population comparison of
visual outcomes and patient satisfaction between 3 modalities for
the correction of low to moderate myopic astigmatism. Clin
Ophthalmol. 2017;11:1253-1263.
- Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid
Measurements as Dry-Eye Score in Patients After LASIK and ICL
Surgery. Presented at American Society of Cataract and Refractive
Surgery (ASCRS) 2012.
- Packer M. The Implantable Collamer Lens with a central port:
review of the literature. Clinical Ophthalmology 2018: 12:
2427–2438.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL”, which includes the EVO Visian ICL™ product line. More than
2,000,000 Visian® ICLs have been sold to date and STAAR markets
these lenses in over 75 countries. To learn more about the ICL go
to: www.evoicl.com. Headquartered in Lake Forest, CA, the company
operates manufacturing and packaging facilities in Aliso Viejo, CA,
Monrovia, CA and Nidau, Switzerland. For more information, please
visit the Company’s website at www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: product safety, effectiveness, or performance for any
particular patient, and any statements of assumptions underlying
any of the foregoing. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include risks factors set forth in the
Company’s Annual Report on Form 10-K for the year ended December
30, 2022 under the caption “Risk Factors,” which is on file with
the Securities and Exchange Commission and available in the
“Investor Information” section of the company’s website under the
heading “SEC Filings.” We disclaim any intention or obligation to
update or revise any forward-looking statements due to new
information or events. These statements are based on expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those described in the
forward-looking statements.
Important Safety Information for EVO
ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing.
For additional information with potential benefits, risks and
complications please visit evoicl.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809191942/en/
5W Public Relations EVO@5wpr.com
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024